You've got the sequence.
ALiCE® makes the protein.
New Title
This animation visualizes the mini-protoplast containing the concentrated protein production machinery of the living cell.
Meet ALiCE® - Radically simple biomanufacturing
No more cell-line development. No more upstream process development.
ALiCE® is cell-based biomanufacturing without the cells.
Explore the capabilities of our protein production platform technology.
One protein expression platform, any protein
Fast
Protein produced in days
Versatile
no protein is too difficult
Scalable
one platform at any scale
Easy
plug and play to existing processes
ALiCE is available as a protein service
We offer an end-to-end protein service for research-grade protein expression. From cloning to expression and purification, we enable our customers to unlock new potential for their research projects, without occupying their own resources.
ALiCE® as a kit
ALiCE is available as a protein expression kit in three different sizes for small-scale protein expression for research purposes.
ALiCE® at scale
Interested in producing your protein of interest in large amounts? Contact our sales team.
Latest news and updates
A therapeutic target like no other
With unmatched therapeutic potential, GPCRs account for ~35% of FDA-approved drugs, achieving the status of the most common class of therapeutic target. They also happen to be one of the most challenging classes of protein to express. In this case study, we explore the rapid expression and in-lysate functional analysis of the CB2 GPCR using the ALiCE® expression system.
Plant-based ALiCE technology could shave weeks off vaccine production
LenioBio has received CEPI (Coalition for Epidemic Preparedness Innovations) funding of up to US $2 million to provide preclinical proof-of-concept that their commercially available, plant-based, and cell-free technology can produce proteins for use in clinical trials testing vaccines against epidemic and pandemic threats in 20-40 days.
Scaling eukaryotic cell-free protein synthesis
In our latest publication in the Journal of Biotechnology and Bioengineering, we describe the production and functional analysis of complex proteins using ALiCE, and showcase scaling in the system – a first for eukaryotic cell-free.
Why your membrane protein expression might be failing, and how to rescue it
Challenging to express, membrane proteins exhibit instability, low yields, and aggregation issues. Optimizing expression is essential from target characterization to clinical candidate selection. In this article, we address potential expression failures and strategies to overcome them.
Contact us
Homepage Contact Us
Locations
Head Office
LenioBio GmbH
Erkrather Str. 401 , 40231 Düsseldorf
Technology & Innovation Center
c/o Fraunhofer IME Building
Forckenbeck Str. 6, 52074 Aachen
